Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is projected to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Kyverna Therapeutics to announce earnings of ($0.67) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kyverna Therapeutics Stock Up 2.9%

KYTX traded up $0.22 during midday trading on Tuesday, reaching $7.73. The company’s stock had a trading volume of 205,545 shares, compared to its average volume of 945,012. Kyverna Therapeutics has a 1 year low of $2.80 and a 1 year high of $13.67. The stock’s 50-day moving average is $8.12 and its 200-day moving average is $8.51. The firm has a market capitalization of $469.91 million, a price-to-earnings ratio of -2.36 and a beta of 1.93. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYTX. Public Employees Retirement System of Ohio purchased a new position in Kyverna Therapeutics in the third quarter worth about $28,000. Qube Research & Technologies Ltd purchased a new stake in shares of Kyverna Therapeutics during the second quarter valued at approximately $43,000. Rhumbline Advisers grew its holdings in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after buying an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Kyverna Therapeutics during the third quarter valued at approximately $77,000. Finally, Bank of America Corp DE increased its position in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

KYTX has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. JPMorgan Chase & Co. lowered their price objective on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kyverna Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.